Instituto de Investigación Sanitaria La Fe-ko ikertzaileekin lankidetzan egindako argitalpenak (13)

2024

  1. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

  2. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

  3. Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study

    Leukemia

  4. Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry

    Haematologica

2023

  1. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

    Blood Cancer Journal, Vol. 13, Núm. 1

  2. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

    Cancers, Vol. 15, Núm. 2

2022

  1. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries

    Blood Cancer Journal, Vol. 12, Núm. 7

  2. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

    Cancers, Vol. 14, Núm. 23

  3. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

    Leukemia, Vol. 36, Núm. 4, pp. 913-922

  4. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

    Blood Advances, Vol. 6, Núm. 4, pp. 1278-1295

2021

  1. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

    British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717

2020

  1. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

2019

  1. Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

    Nucleic Acids Research, Vol. 47, Núm. 10, pp. 5016-5037